#Japan #Tokyo #Tohoku University #Regenosome #Hypoxic Wellness

Investigating Low Oxygen Wellness: A New Initiative

In an innovative collaboration, Regenosome Inc., based in Minato City, Tokyo, has initiated a proof-of-concept trial focusing on the impact of hypoxic environments on blood glucose levels and aging. This initiative is in partnership with Tohoku University’s Faculty of Medicine under the guidance of Assistant Professor Nakai Takashi. The kickoff event for this program, titled "Low Oxygen Wellness - Proof of Concept Kickoff Event," was held on October 6, 2025, at THE LINKPILLAR 1 NORTH 6F・7F in Takanawa Gateway Link Scholars’ Hub (LiSH).

Event Overview

The kickoff event showcased various presentations pertinent to the initiative:

• - Kohei Miyajima from East Japan Railway Company explained the broader startup ecosystem centered around Takanawa Gateway City and LiSH.
• - Yentaro Sakuma, CEO of Regenosome, provided an overview of the company's objectives.
• - Assistant Professor Takashi Nakai elaborated on the specifics of the hypoxic environment experiment.
• - Kenzo Suzuki, CEO of Regenosome, discussed a concept utilizing low oxygen environments for projects related to aging.
• - Daigo Okada, a special assistant professor from Gifu University, shared insights on utilizing DNA methylation data for an "epigenetic clock".
• - The day concluded with a networking event encouraging connection among researchers and potential investors.

During the event, participants had an opportunity to immerse themselves in a simulated hypoxic environment designed to mirror conditions at an elevation of 3,000 meters. Demonstrations showcasing blood glucose measurement allowed stakeholders to grasp the potential impacts of such environments.

Objectives of the Proof-of-Concept Trial

The aim of this trial is to evaluate the effects of hypoxia on adult participants working in LiSH. Over a period of four weeks, 20 adults will undergo low oxygen interventions for one hour a day, three to five times a week, while maintaining their usual work activities. Measurements of blood glucose levels, blood pressure, and salivary DNA methylation will be taken throughout the trial. This research seeks to scientifically validate the effects of hypoxic environments on blood sugar management and aging inhibition, with the possibility of applications in wellness technology and space medicine in the future.

Vision for the Future

Kenzo Suzuki commented on the significance of this trial: "This proof-of-concept will explore the prospects of solving health issues on Earth. We designed it so that participants can experience a hypoxic environment while working. Our primary goal is to integrate future wellness into everyday life."

Looking Ahead

Regenosome plans to utilize data collected from this experiment, which will begin in 2025, to develop new wellness products and healthcare programs based on hypoxic adaptations. Collaborating with stakeholders, including their parent company, Space Seed Holdings, they aim to establish a longevity-focused ecosystem dedicated to applying terrestrial scientific advancements to outer space. This will involve fostering partnerships with universities, research institutions, and companies both domestically and internationally.

About Regenosome Inc.

Regenosome endeavors to provide innovative solutions aimed at aging suppression and regenerative medicine through technologies such as nanoparticles and exosomes. The company will establish its headquarters and research facility, the Takanawa Longevity Laboratory, at LiSH in May 2025 to accelerate business and research development. Ultimately, they strive for advancements in medical technology and offer novel solutions in the realm of space medicine, contributing to the extension of healthy lifespan and human exploration of space. Regenosome

About Space Seed Holdings Inc.

Space Seed Holdings operates as a deep-tech venture builder, dedicated to making science fiction a reality through investment, research, and business creation. Their initiatives, like the "Fermentation and Longevity Fund," focus on societal issue resolution through business innovation. They aim to equip humanity with the necessary technology for living in outer space by 2040, collaborating with various stakeholders. Space Seed Holdings